舒肝宁注射液利胆退黄抗炎护肝机制研究进展*

doi:10.3969/j.issn.1672-5069.2023.05.041

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 765-768.doi: 10.3969/j.issn.1672-5069.2023.05.041

• 综述 • 上一篇

舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*

黄龙, 范雅茜综述, 段钟平审校

100069 北京市首都医科大学附属北京佑安医院肝病中心四科/肝衰竭与人工肝治疗研究北京市重点实验室

收稿日期:2022-05-05 出版日期:2023-09-10 发布日期:2023-09-13
通讯作者: 段钟平,E-mail:duan@ccmu.edu.cn
作者简介:黄龙,男,27岁,硕士研究生。主要从事肝病基础与临床研究。E-mail:18561390078@163.com
基金资助:
^*高层次公共卫生技术人才建设项目资助(学科带头人-01-12);北京市医院管理中心“登峰”计划专项经费资助,编号:DFL20221501;北京市自然科学基金资助项目(编号:7222094)

Mechanism of Shuganning’s roles in promoting gallbladder motion, relieving jaundice, anti-inflammatory and protecting liver functions

Huang Long, Fan Yaxi, Duan Zhongping

Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Fourth Department of Liver Disease Center, You’an Hospital, Capital Medical University, Beijing 100069, China

Received:2022-05-05 Online:2023-09-10 Published:2023-09-13

摘要/Abstract

摘要： 随着中西医结合治疗肝病研究的深入开展,肝病治疗的新方法、新药物不断涌现,中医药单靶点叠加作用、多靶点协同作用和毒性分散效应可为肝病治疗提供更多的思路,成为丰富完善肝病治疗方法的重要路径。舒肝宁注射液是基于经典名方茵陈蒿汤的现代中药制剂。本文从肝脏转运体、代谢酶和核受体等不同角度对舒肝宁的利胆退黄机制进行了分析,从肝巨噬细胞和氧化应激反应两个方面对其抗炎护肝机制进行阐述,以期为舒肝宁注射液现代中药组方的临床用药提供依据。

关键词: 病毒性肝炎, 非酒精性脂肪性肝病, 舒肝宁, 治疗, 机制

Abstract: With the in-depth development of liver disease research with integrated traditional Chinese and Western medicine, new approaches and new medicines for liver disease treatment continue to emerge. The traditional Chinese medicine single-target superposition, multi-target synergistic effects and toxic dispersion effects provide more ideas for liver disease treatment and become a rich source of an important way to improve the treatment of liver disease. In this paper, we introduce the mechanism of Shuganning, a herbal medicine compound, in relieving bile and reducing jaundice from the perspectives as follows: liver transporters, metabolic enzymes and nuclear receptors, and its anti-inflammatory and hepatoprotective mechanism.

Key words: Viral hepatitis, Nonalcoholic fatty liver disease, Shuganning injection, mechanism, Treatment

黄龙, 范雅茜, 段钟平. 舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*[J]. 实用肝脏病杂志, 2023, 26(5): 765-768.

Huang Long, Fan Yaxi, Duan Zhongping. Mechanism of Shuganning’s roles in promoting gallbladder motion, relieving jaundice, anti-inflammatory and protecting liver functions[J]. Journal of Practical Hepatology, 2023, 26(5): 765-768.

参考文献

[1] 赵妍姝. 基于胆红素、胆酸盐转运体和代谢酶系统初探栀子退黄利胆作用的分子机制.兰州大学,2017.
[2] Zhu L, Wang L, Cao F, et al. Modulation of transport and metabolism of bile acids and bilirubin by chlorogenic acid against hepatotoxicity and cholestasis in bile duct ligation rats: involvement of SIRT1-mediated deacetylation of FXR and PGC-1α. J Hepatobiliary Pancreat Sci, 2018,25(3):195-205.
[3] Jia W, Wei M, Rajani C, et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell, 2021,12(5):411-425.
[4] Wahlström A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab, 2016,24(1):41-50.
[5] Soroka CJ, Boyer JL. Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. Mol Aspects Med, 2014,37:3-14.
[6] Chang JH, Plise E, Cheong J, et al. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm, 2013,10(8):3067-3075.
[7] Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev, 2003,83(2):633-671.
[8] Chang JH, Plise E, Cheong J, et al. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm, 2013,10(8):3067-3075.
[9] 黄龙,陈煜,吴桥,等.舒肝宁注射液对于氯丙嗪引起的新型组织工程肝构建的胆汁淤积型药物性肝损伤模型的影响.临床肝胆病杂志,2022,38(3): 587-593.
[10] 赵元辰,苏婷.四个经典方利胆和调整肠道菌群作用的研究.光明中医,2019,34(17):2750-2752.
[11] Yang J, Xiang D, Xiang D, et al. Baicalin protects against 17α-ethinylestradiol-induced cholestasis via the sirtuin1/hepatic nuclear receptor-1α/farnesoid X receptor pathway. Front Pharmacol, 2020,10:1685.
[12] van de Laarschot LF, Jansen PL, Schaap FG, et al. The role of bile salts in liver regeneration. Hepatol Int, 2016,10(5):733-740.
[13] Liu B, Li Y, Ji H, et al. Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2. Can J Physiol Pharmacol, 2017,95(2):215-223.
[14] Zhong D, Xie Z, Huang B, et al.Ganoderma lucidum polysaccharide peptide alleviates hepatoteatosis via modulating bile acid metabolism dependent on FXR-SHP/FGF. Cell Physiol Biochem, 2018,49(3):1163-1179.
[15] McGettigan BM, McMahan RH, Luo Y, et al. Sevelamer improves steatohepatitis, Inhibits Liver and intestinal farnesoid X receptor (FXR), and reverses innate immune dysregulation in a mouse model of non-alcoholic fatty liver disease. J Biol Chem, 2016,291(44):23058-23067.
[16] 王青,苏聪平,张惠敏,等.从炎性反应角度探讨清热解毒药的作用机制.中国中药杂志,2018,43(18):3787-3794.
[17] Shan Z, Ju C. Hepatic macrophages in liver injury. Front Immunol, 2020,11:322.
[18] Lu S, Wang Y, Liu J. Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies. J Genet Genomics, 2021,28:S1673.
[19] Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004,25(6):280-288.
[20] 朱志辉.舒肝宁联合异甘草酸镁治疗急性肝炎的临床疗效观察.基层医学论坛,2021,25(35):5173-5175.
[21] 朱永辉,邓维成,何永康,等.舒肝宁注射液对晚期血吸虫病肝纤维化患者血清转化生长因子β1、γ-干扰素水平的影响.中国老年学杂志,2012,32(8):1592-1593.
[22] Naveed M, Hejazi V, Abbas M, et al. Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed Pharmacother,2018,97:67-74.
[23] Jiang Y, Nan H, Shi N, et al. Chlorogenic acid inhibits proliferation in human hepatoma cells by suppressing noncanonical NF-κB signaling pathway and triggering mitochondrial apoptosis. Mol Biol Rep, 2021,48(3):2351-2364.
[24] Xin X, Jin Y, Wang X, et al. A combination of geniposide and chlorogenic acid combination ameliorates nonalcoholic steatohepatitis in mice by inhibiting Kupffer cell activation. Biomed Res Int, 2021,2021:6615881.
[25] Jang E, Kim BJ, Lee KT, et al. A survey of therapeutic effects of artemisia capillaris in liver diseases. Evid Based Complement Alternat Med,2015,2015:728137.
[26] Zhong X, Liu H. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways. Biomed Pharmacother, 2018,98:111-117.
[27] Chen YS, Chen QZ, Wang ZJ, et al. Anti-inflammatory and hepatoprotective effects of ganoderma lucidum polysaccharides against carbon tetrachloride-induced liver injury in Kunming mice. Pharmacology, 2019,103(3-4):143-150.
[28] García-Ruiz C, Fernández-Checa JC. Mitochondrial oxidative stress and antioxidants balance in fatty liver disease. Hepatol Commun, 2018,2(12):1425-1439.
[29] Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem, 2001,11(4):173-186.
[30] Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med, 2010,49(11):1603-1616.
[31] 高文,张晓慧,张译之,等。舒肝宁注射液对非酒精性脂肪性肝病组织工程肝保护作用的机制研究.中西医结合肝病杂志,2022,32(3):248-251.
[32] Zhao T, Wang Q. Capillarisin protects SH-SY5Y cells against bupivacaine-induced apoptosis via ROS-mediated PI3K/PKB pathway. Life Sci,2020,259:118279.
[33] Shin JK, Lee SM. Genipin protects the liver from ischemia/reperfusion injury by modulating mitochondrial quality control. Toxicol Appl Pharmacol, 2017,328:25-33.
[34] Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology, 2007,46(2):590-597.
[35] Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene, 2008,27(48):6228-6244.
[36] Lee TY, Chang HH, Chen JH, et al. Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats. J Ethnopharmacol,2007,109(2):318-324.

舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*

Mechanism of Shuganning’s roles in promoting gallbladder motion, relieving jaundice, anti-inflammatory and protecting liver functions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[2]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[3]	彭真, 宁会彬, 李宽, 尚佳. HBeAg阳性慢性HBV 感染分期和治疗新进展[J]. 实用肝脏病杂志, 2023, 26(5): 615-617.
[4]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[5]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[6]	李亚玲, 杨发成, 蒋亚西. 直接抗病毒药物治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 638-641.
[7]	蔡涛, 魏玮, 王欣雯, 王玥坤, 秦军, 蓝晓红. 直接抗病毒药物治疗慢性终末期肾病合并慢性丙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 642-645.
[8]	吴非, 郭雯, 张群. 非酒精性脂肪性肝病患者骨骼肌质量变化研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 646-649.
[9]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[10]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[11]	武向慧, 李龙虎, 景斐华, 武鹏. 经导管动脉化疗栓塞联合射频消融治疗肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 702-705.
[12]	陈长广, 肖荣, 王俊. DEB-TACE序贯射频消融治疗原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 706-709.
[13]	张树庚, 张少博, 朱泽斌, 栗雪峰, 蔡伟, 郭亚飞, 刘连新. Clavien-Dindo分级系统分析不同供肝类型肝移植患者术后早期并发症发生率比较研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 738-741.
[14]	叶超荣, 张涛, 吴永军, 利民. LCBDE与ERCP术治疗胆总管结石患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 742-745.
[15]	宋巍, 李智德, 李玉鹏, 陈雄. 吲哚菁绿荧光显像指导腹腔镜胆囊切除术治疗胆囊良性疾病患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 746-749.